NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumor mutation burden for high-risk stage 2 or stage 3 deficient-MMR/MSI-high colorectal cancer
Shiu, K. K. Seligmann, J. F. Graham, J. Wilson, R. H. Saunders, Mark P Iveson, T. Kayhanian, H. Khan, K. H. Rodriguez-Justo, M. Jansen, M.
Shiu, K. K.
Seligmann, J. F.
Graham, J.
Wilson, R. H.
Saunders, Mark P
Iveson, T.
Kayhanian, H.
Khan, K. H.
Rodriguez-Justo, M.
Jansen, M.
Citations
Altmetric:
Abstract
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Shiu KK, Seligmann JF, Graham J, Wilson RH, Saunders MP, Iveson T, et al. NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumor mutation burden for high-risk stage 2 or stage 3 deficient-MMR/MSI-high colorectal cancer. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680304912.